CIK 0001501989 · Accelerated filer
CytomX Therapeutics, Inc.
Sign in to watch- Ticker
- CTMX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273521219
- Phone
- 650.515.3185
- Business address
- 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- 4/A Planned sale CEO sold 101,793 shares at $4.54 ($461,906)
- 4 Grant or award Chief Legal Officer acquired 100,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Financial Officer sold 1,624 shares at $3.05 ($4,953)
- 4 Open-market sale Chief Medical Officer sold 21,279 shares at $6.42 ($136,675)
- 4 Planned sale CEO sold 118,969 shares at $6.42 ($764,138)
- 4 Open-market sale SVP, Chief Scientific Officer sold 31,492 shares at $6.42 ($202,273)
- 4 Open-market sale Chief Financial Officer sold 19,323 shares at $6.42 ($124,112)
- 4 Grant or award Chief Business Officer acquired 20,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 75,000 shares (grant or award)
- 4 Grant or award SVP, Chief Scientific Officer acquired 60,000 shares (grant or award)
Page 1 of 20 · 400 filings